Autoimmune Liver Disease Overview

Principles

Definition

Autoimmune liver disease is a research concept within hepatology and immunology focused on the investigation of a group of chronic inflammatory conditions characterized by immune-mediated destruction of hepatocytes and/or bile ducts. This field examines the underlying immunological mechanisms, genetic predispositions, diagnostic criteria, therapeutic strategies, and long-term outcomes associated with these specific forms of liver pathology.

Ontological type

Therapeutic Management

Immunopathogenesis

Diagnostic Criteria

Key developments

Key Figures

Serology and Antigen Discovery era

Ian R. Mackay [1], affiliated with University of California, San Francisco [3] and Icahn School of Medicine at Mount Sinai [4], was a key figure in the Serology and Antigen Discovery era (1969-1997). His notable contribution in this era was the Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis [7], a finding that provided a molecular target for serologic assays and helped translate immunologic signatures into diagnostic taxonomies. M. Eric Gershwin [2], with Stanford University [5] and The University of Texas Southwestern Medical Center [6], contributed to the Serology and Antigen Discovery era through the same foundational work on the 70 kd mitochondrial antigen. This work on the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis [7] helped establish disease-specific serologic markers and reinforced the era's shift toward molecular serology for classifying autoimmune liver diseases.

Diagnostic Standardization and Overlap era

Keith D. Lindor [1] emerges as a central figure in this era, with affiliations including La Roche College [3] and the University of Washington [4], shaping the collaborative landscape of autoimmune liver disease. His contributions to diagnostic standardization are evidenced by analyses in the Primary Biliary Cirrhosis [7] paper and the Incidence and Risk Factors for Cholangiocarcinoma in Primary Sclerosing Cholangitis [8] paper, which collectively advanced reproducible serologic, histologic, and clinical criteria that underpinned surveillance and risk stratification in this era. M. Eric Gershwin [2] likewise figures prominently in this period, with institutional work at University of California, Davis [5] and Universidad de Navarra [6]. Gershwin's sole listed contribution in this era centers on Primary Biliary Cirrhosis [7] (2011), a cornerstone in delineating autoimmune liver disease phenotypes and overlaps that fortified standardized definitions and informed management strategies.

Personalized Steroid-Sparing Therapy era

Kenya Honda [1], affiliated with Keio University [2], has been a key figure in the Personalized Steroid-Sparing Therapy era (2017–2023) for autoimmune liver disease. Her notable contribution centers on the 2019 paper Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis [3], which underscored the gut-liver axis as a mechanistic target for precision immunomodulation in PSC. Honda's [1] work at Keio University [2] laid groundwork for microbiome-informed risk stratification and steroid-sparing regimens, highlighting how gut immune pathways can shape therapeutic choices in this era. Together, these contributions established a blueprint for precision immunomodulatory care in autoimmune hepatology during this era.